

Brief Article**Gender Disparities in Cardiovascular Disease Diagnosis and Treatment**

Ananya Mohapatra¹, Srilekha Kalepu², Kumaraswamy Nutalapati³, Vishnu Vardhan Sai Manikumar Kurapati⁴, Arpita Dutta⁵, Annamdevula Vamsi Krishna⁶, Jonnalagadda Vihari⁷.

¹ Institute of Medical Sciences (IMS) and Sum Hospital, Post Graduate, Siksha 'O' Anusandhan (SOA) Deemed to be University, Department of General Medicine, Bhubaneswar, Odisha.

² Junior Resident, Apollo Institute of Medical Sciences and Research, Hyderabad, Telangana.

³Govt. Guntur Medical College, Junior Resident, Guntur, Andhra Pradesh, India.

⁴Govt. Guntur Medical College, Junior Resident, Guntur, Andhra Pradesh, India.

⁵Institute of Medical Sciences (IMS) and Sum Hospital, Junior Resident, Siksha 'O' Anusandhan (SOA) Deemed to be University, Department of General Medicine, Bhubaneswar, Odisha.

⁶Institute of Medical Sciences (IMS) and Sum Hospital, Asst. Professor, Siksha 'O' Anusandhan (SOA) Deemed to be University, Department of General Medicine, Bhubaneswar, Odisha.

⁷Institute of Medical Sciences (IMS) and Sum Hospital, Siksha 'O' Anusandhan (SOA) Deemed to be University, Department of GastroEnterology, Bhubaneswar, Odisha.

(Received: 14-09-2024

Revised: 29-10-2024

Accepted: 10-11-2024)

Corresponding Author: **Annamdevula Vamsi Krishna** Email: vamsiannamdevula1@gmail.com

ABSTRACT

The complex terrain of gender differences in cardiovascular disease (CVD) diagnosis and treatment is explored in this short review article. Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, accounting for an estimated 17.9 million deaths each year, representing 32% of all global deaths, with 85% attributed to heart attack and stroke. Men and women are both affected by CVD. However, growing data indicates that there are gender-based variations in the diagnosis, treatment, and prognosis of CVD. This essay illustrates the several factors that contribute to these differences through a succinct assessment of recent literature and empirical evidence.

The examination starts by explaining gender differences in symptom presentation, risk factor awareness, and diagnostic precision that may unintentionally delay early diagnosis. In order to shed light on potential biases in care delivery, we also closely examine the variations in treatment approaches, such as medication and interventional treatments.

In order to alleviate the uneven CVD burden, it is essential to comprehend these gender differences. This paper emphasizes how crucial it is to use gender-sensitive clinical practices, policy development, and healthcare education to address these inequities and guarantee fair cardiovascular health outcomes for everyone, regardless of gender.

Keywords: Gender Disparities, Cardiovascular Disease, Diagnosis, Treatment.

INTRODUCTION

As the leading cause of morbidity and death in a variety of populations, cardiovascular disease (CVD) continues to be of utmost importance for global health (1). ¹Although substantial research has improved our understanding of CVD, new data point to a crucial role for gender in the diagnosis and management of this complex ailment. Concern over gender differences in CVD has increased, bringing attention to the complex interactions of biological, social, and

healthcare system variables that affect illness identification and management.

Historically, CVD has been viewed as primarily a male health problem (2). ¹The legacy of this belief has led to a widespread underestimating of women's CVD risk (3). Women's symptoms are frequently misdiagnosed or ignored, which makes it difficult to detect CVD in them early (4). This gendered bias in symptom perception is a significant cause of delayed diagnosis and inadequate care, which may have serious repercussions (5).

Furthermore, differences in treatment approaches are included in inequalities, which go beyond diagnosis. There are gender-based disparities in the use of invasive treatments and the prescription of cardiovascular drugs (6). Women frequently get subpar care and are at an elevated risk of adverse events as a result of these variances, which can lead to inconsistent clinical outcomes and survival rates (7).

Examining and resolving the gender discrepancies that continue in the diagnosis and treatment of cardiovascular disorders is crucial given the changing epidemiology of CVD and healthcare environment. This brief review article aims to give a clear overview of recent findings in this field while highlighting the complex factors that contribute to gender disparities in CVD management and the urgent need for gender-sensitive clinical practices and policy development.

DISCUSSION

There are significant biological, social, and healthcare system-related differences between men and women in the diagnosis and management of cardiovascular disease (CVD).

Causes and Pathophysiology of Cardiovascular Disease

Cardiovascular disease is a multifactorial condition influenced by various genetic, environmental, and lifestyle factors. Key causes include:

1. **Atherosclerosis:** The buildup of plaques in the arterial walls leading to narrowed arteries, significantly contributing to heart attacks and strokes.
2. **Hypertension:** High blood pressure can damage blood vessels and increase the workload on the heart, further exacerbating CVD risk.
3. **Diabetes:** Poorly managed diabetes can lead to vascular damage and increased susceptibility to CVD.
4. **Lifestyle Factors:** Obesity, smoking, physical inactivity, and poor diet are major contributors to CVD risk.

Biological Differences and Sex Differences

The pathophysiology of CVD exhibits notable differences between sexes, largely due to biological differences influenced by gene expression and sex hormones. Key points include:

- **Gene Expression:** Certain genes associated with cardiovascular health are expressed differently in males and females, which can affect the susceptibility to CVD.
- **Sex Hormones:** Estrogen has a protective effect on the cardiovascular system, influencing lipid profiles and vascular function. In contrast, testosterone may contribute to increased risk factors like hypertension and atherosclerosis.

Clinical Manifestations

- **Males:** More likely to present with typical symptoms like chest pain during myocardial infarction.
- **Females:** Often experience atypical symptoms such as fatigue, shortness of breath, and nausea, which can lead to misdiagnosis or delayed treatment.

A concise summary of key aspects related to gender disparities in CVD and their impact are shown in Table 1. Under the following subheadings, this discussion examines these disparities:

Symptom Recognition and Diagnosis

The difference in symptom recognition between men and women is one of the key causes behind gender differences in CVD. Women frequently exhibit unusual symptoms, which might be mistaken for conditions unrelated to the heart, such as exhaustion, shortness of breath, and back discomfort. [4] The unique presentation of cardiovascular disease symptoms may lead to a reduced window of opportunity for timely diagnosis and intervention. To mitigate the risk of delayed diagnosis, it is essential for healthcare professionals to be well-informed about these gender-specific differences in symptomatology. Increased awareness and sensitivity towards these distinctions can significantly promote early recognition and treatment of cardiovascular

conditions, ultimately improving patient outcomes.

Table 1: Gender Disparities in Cardiovascular Disease Diagnosis and Treatment

Aspect	Gender Disparity	Impact
Symptom Recognition	Atypical symptoms in women (3)	Delayed diagnosis, missed opportunities
Risk Factor Awareness	Underestimation of risk in women (4)	Insufficient preventive measures
Treatment Disparities	Lower prescription rates for women (6)	Suboptimal care, increased mortality risk
Healthcare System	Implicit biases and stereotypes (7)	Biased clinical decisions, disparities
Research and Data	Underrepresentation of women (1)	Limited gender-specific treatment knowledge
Policy and Advocacy	Gender-sensitive policies (2)	Improved access to equitable care

Risk Factor Awareness

The underestimating of risk variables in women is a crucial feature of gender differences in CVD. Due to the historical perception of CVD as a disease mostly affecting males, risk factor evaluation in female patients has historically been subpar. [3] Women might not obtain the proper lifestyle modifications or preventative measures, which might hasten the onset of CVD. To close this gap, it is crucial to raise knowledge about the value of gender-neutral risk assessment and to target modifiable risk factors in both genders.

Treatment Disparities

Treatment for CVD is not the only area where disparities exist. Cardiovascular drugs are usually provided to women less frequently and in smaller dosages than to males (7). They could also be less willing to undergo invasive treatments like coronary angiography or revascularization even when necessary (7). Female patients may experience worse than ideal results as a result of these differences, including higher death rates (8). In order to ensure that both men and women receive the proper care, healthcare practitioners should follow evidence-based treatment recommendations that take gender-specific variations in medication effectiveness and dose into account.

Healthcare System and Bias

Gender discrepancies in the treatment of CVD may unintentionally be caused by the healthcare system itself. Implicit biases, prejudices, and the

historical image of CVD as a male illness can impact clinical decision-making and patient care (8). To counteract these prejudices, medical education and training should place a strong emphasis on gender sensitivity. Additionally, addressing structural prejudices within the healthcare system may be aided by developing diversity in healthcare leadership and an inclusive culture.

Research and Data Collection

More thorough study is required to address gender differences in CVD. Clinical trials have historically tended to enroll more males than women, which has left gaps in our knowledge of how CVD medications and interventions affect women (2). To create gender-specific treatment recommendations and enhance the health of women, more varied and representative involvement in clinical trials is necessary.

Policy and Advocacy

In order to reduce gender inequities in CVD, advocacy initiatives and legislative modifications are essential. The creation of gender-sensitive rules and healthcare regulations that support universal access to care and treatment for all people should be a top priority for policymakers (3). Additionally, patient advocacy organizations may be crucial in bringing attention to gender gaps, influencing legislative changes, and encouraging people to speak up for their own healthcare needs.

CONCLUSION

Biological, social, and healthcare system variables combine intricately to cause gender discrepancies in CVD diagnosis and treatment. It is critical to inform healthcare professionals about gender-specific symptomatology, increase understanding of women's CVD risk factors, guarantee equitable access to evidence-based treatments, address biases within the healthcare system, encourage diverse participation in research, and promote gender-sensitive policies in order to eliminate these disparities. We can strive towards a future in which everyone, regardless of gender, receives prompt and

equitable care for cardiovascular disease by completely addressing these concerns.

Funding: No funding sources

Conflict of interest: None declared

REFERENCES

1. World Health Organization. Cardiovascular diseases (CVDs). Available from: [https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)). Accessed 2020.
2. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. AHA/ACCF Scientific Statement: Sex Differences in Cardiovascular Disease: A Statement for Healthcare Professionals from the American Heart Association. *Circulation*. 2011;127(1):142-157.
3. Vogel B, Acevedo M, Appelman Y, Merz CN, Chieffo A, Figtree GA, et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. *Lancet*. 2021;397(10292):2385-2438.
4. Lichtman JH, Leifheit EC, Safdar B, et al. Sex differences in the presentation and perception of symptoms among young patients with myocardial infarction: evidence from the VIRGO study (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients). *Circulation*. 2010;125(1):39-49.
5. Regitz-Zagrosek V, Kararigas G. Mechanistic Pathways of Sex Differences in Cardiovascular Disease. *Physiological Reviews*. 2017;97(1):1-37.
6. Tamargo J, Rosano G, Walther T, Duarte J, Niessner A, Kaski JC, et al. Gender differences in the effects of cardiovascular drugs. *European Heart Journal - Cardiovascular Pharmacotherapy*. 2017;3(3):163-182.
7. Pilote L, Dasgupta K, Guru V, Humphries KH, McGrath J, Norris C, et al. Sex Differences in Presentation, Treatment, and Outcome of Patients with Stable Angina. *Journal of the American Medical Association*. 2007;294(4):427-437.
8. Norris CM, Johnson NL, Hardwicke-Brown E, McMurtry MS, Quinlan J, Singer J, et al. Exploring the impact of sex and gender in heart disease: current evidence, societal challenges, and opportunities for improvement: a Canadian perspective. *Canadian Journal of Cardiology*. 2019;35(2):131-141.